FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165432856> ?p ?o ?g. }

• W3165432856 endingPage "1119" @default.
• W3165432856 startingPage "1112" @default.
• W3165432856 abstract "Abstract Chronic lymphocytic leukemia (CLL)‐related symptoms impair the well‐being of patients, making improvement of health‐related quality of life (QoL) a goal of treatment. The CLL14 trial demonstrated higher efficacy of fixed‐duration venetoclax‐obinutuzumab (Ven‐Obi) compared to chlorambucil‐obinutuzumab (Clb‐Obi) in patients with previously untreated CLL. To assess patients' QoL, the following patient‐reported outcomes (PRO) measures were assessed: the M.D. Anderson Symptom Inventory (MDASI) core instrument and CLL module and the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30). At treatment start, physical functioning (mean 75.9 [standard deviation (SD) ± 20.1] in the Clb‐Obi arm and 76.9 [±19.4] in the Ven‐Obi arm), role functioning (73.6 [±27.86] and 72.6 [±26.9]) and GHS/QoL (63.6 [±21.0] and 60.3 [±20.5]) were comparable between treatment arms per EORTC QLQ‐C30 scale scores. Baseline levels of physical and role functioning were maintained throughout treatment and follow‐up, with no relevant improvement or deterioration. On average, patients treated with Ven‐Obi showed a meaningful improvement of GHS/QoL during treatment and follow‐up by at least eight points at cycle three, whereas improvement was delayed until cycle eight with Clb‐Obi. According to MDASI scores, CLL symptoms (1.5 [±1.2] and 1.6 [±1.3]), core cancer symptoms (1.5 [±1.4] and 1.8 [±1.7]) and symptom interference (2.1 [±2.3] and 2.3 [±2.3]) were generally low and comparable between treatment arms at baseline and were maintained throughout treatment and follow‐up. This analysis demonstrates that the higher efficacy of Ven‐Obi is not associated with QoL impairment and that Ven‐Obi achieves early relief of CLL‐related symptoms in elderly unfit patients." @default.
• W3165432856 created "2021-06-07" @default.
• W3165432856 creator A5011257275 @default.
• W3165432856 creator A5018804552 @default.
• W3165432856 creator A5042484292 @default.
• W3165432856 creator A5043764554 @default.
• W3165432856 creator A5044687687 @default.
• W3165432856 creator A5061682665 @default.
• W3165432856 creator A5068999880 @default.
• W3165432856 creator A5074940007 @default.
• W3165432856 creator A5076077834 @default.
• W3165432856 creator A5076252609 @default.
• W3165432856 creator A5085633786 @default.
• W3165432856 creator A5088826331 @default.
• W3165432856 date "2021-06-22" @default.
• W3165432856 modified "2023-10-06" @default.
• W3165432856 title "Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 <scp>CLL14</scp> trial" @default.
• W3165432856 cites W2018304470 @default.
• W3165432856 cites W2031191067 @default.
• W3165432856 cites W2120319857 @default.
• W3165432856 cites W2135001286 @default.
• W3165432856 cites W2143104078 @default.
• W3165432856 cites W2150906637 @default.
• W3165432856 cites W2160782995 @default.
• W3165432856 cites W2513641012 @default.
• W3165432856 cites W2762027870 @default.
• W3165432856 cites W2773288532 @default.
• W3165432856 cites W2790385276 @default.
• W3165432856 cites W2791345134 @default.
• W3165432856 cites W2899353411 @default.
• W3165432856 cites W2914279987 @default.
• W3165432856 cites W2948436219 @default.
• W3165432856 cites W2980937306 @default.
• W3165432856 cites W3003468352 @default.
• W3165432856 cites W3005820875 @default.
• W3165432856 cites W3016538158 @default.
• W3165432856 cites W3047549757 @default.
• W3165432856 cites W3082899459 @default.
• W3165432856 doi "https://doi.org/10.1002/ajh.26260" @default.
• W3165432856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34050972" @default.
• W3165432856 hasPublicationYear "2021" @default.
• W3165432856 type Work @default.
• W3165432856 sameAs 3165432856 @default.
• W3165432856 citedByCount "4" @default.
• W3165432856 countsByYear W31654328562022 @default.
• W3165432856 countsByYear W31654328562023 @default.
• W3165432856 crossrefType "journal-article" @default.
• W3165432856 hasAuthorship W3165432856A5011257275 @default.
• W3165432856 hasAuthorship W3165432856A5018804552 @default.
• W3165432856 hasAuthorship W3165432856A5042484292 @default.
• W3165432856 hasAuthorship W3165432856A5043764554 @default.
• W3165432856 hasAuthorship W3165432856A5044687687 @default.
• W3165432856 hasAuthorship W3165432856A5061682665 @default.
• W3165432856 hasAuthorship W3165432856A5068999880 @default.
• W3165432856 hasAuthorship W3165432856A5074940007 @default.
• W3165432856 hasAuthorship W3165432856A5076077834 @default.
• W3165432856 hasAuthorship W3165432856A5076252609 @default.
• W3165432856 hasAuthorship W3165432856A5085633786 @default.
• W3165432856 hasAuthorship W3165432856A5088826331 @default.
• W3165432856 hasBestOaLocation W31654328561 @default.
• W3165432856 hasConcept C126322002 @default.
• W3165432856 hasConcept C143998085 @default.
• W3165432856 hasConcept C159110408 @default.
• W3165432856 hasConcept C168563851 @default.
• W3165432856 hasConcept C1862650 @default.
• W3165432856 hasConcept C2776694085 @default.
• W3165432856 hasConcept C2776755627 @default.
• W3165432856 hasConcept C2777607594 @default.
• W3165432856 hasConcept C2777866208 @default.
• W3165432856 hasConcept C2777938653 @default.
• W3165432856 hasConcept C2778461978 @default.
• W3165432856 hasConcept C2779675984 @default.
• W3165432856 hasConcept C2779951463 @default.
• W3165432856 hasConcept C71924100 @default.
• W3165432856 hasConcept C90924648 @default.
• W3165432856 hasConceptScore W3165432856C126322002 @default.
• W3165432856 hasConceptScore W3165432856C143998085 @default.
• W3165432856 hasConceptScore W3165432856C159110408 @default.
• W3165432856 hasConceptScore W3165432856C168563851 @default.
• W3165432856 hasConceptScore W3165432856C1862650 @default.
• W3165432856 hasConceptScore W3165432856C2776694085 @default.
• W3165432856 hasConceptScore W3165432856C2776755627 @default.
• W3165432856 hasConceptScore W3165432856C2777607594 @default.
• W3165432856 hasConceptScore W3165432856C2777866208 @default.
• W3165432856 hasConceptScore W3165432856C2777938653 @default.
• W3165432856 hasConceptScore W3165432856C2778461978 @default.
• W3165432856 hasConceptScore W3165432856C2779675984 @default.
• W3165432856 hasConceptScore W3165432856C2779951463 @default.
• W3165432856 hasConceptScore W3165432856C71924100 @default.
• W3165432856 hasConceptScore W3165432856C90924648 @default.
• W3165432856 hasFunder F4320309117 @default.
• W3165432856 hasFunder F4320309432 @default.
• W3165432856 hasIssue "9" @default.
• W3165432856 hasLocation W31654328561 @default.
• W3165432856 hasOpenAccess W3165432856 @default.
• W3165432856 hasPrimaryLocation W31654328561 @default.
• W3165432856 hasRelatedWork W1809182350 @default.
• W3165432856 hasRelatedWork W2593078472 @default.

• next